Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
The objective was to review the published literature for Canadian studies that provided information on the following question: What are the costs associated with specialized anticoagulation services?
Contents
- ABBREVIATIONS
- 1. INTRODUCTION
- 2. CONTEXT AND POLICY ISSUES
- 3. RESEARCH QUESTION
- 4. KEY FINDINGS
- 5. METHODS
- 6. RESULTS
- 7. DISCUSSION
- 8. CONCLUSIONS
- REFERENCES
- APPENDIX 1 EXPERT COMMITTEE AND CONTRIBUTORS
- APPENDIX 2 DEFINITIONS OF ANTICOAGULATION MANAGEMENT SERVICES
- APPENDIX 3 QUALITY ASSESSMENT USING BMJ CHECKLIST
- APPENDIX 4 SUMMARY OF INCLUDED STUDIES
- APPENDIX 5 SUMMARY OF SCHULMAN ET AL.
- APPENDIX 6 SUMMARY OF LALONDE ET AL.
- APPENDIX 7 SUMMARY OF BUNGARD ET AL.
This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). This report contains a review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared, and it was guided by expert input and advice throughout its preparation.
The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report.
CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.
Production of this report is made possible through a financial contribution from Health Canada.
- Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation
- Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence
- Recommendations for Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation
- Warfarin Management in Patients with Atrial Fibrillation — Current Practice Study
- NLM CatalogRelated NLM Catalog Entries
- Review A review of the cost of atrial fibrillation.[Value Health. 2012]Review A review of the cost of atrial fibrillation.Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. Value Health. 2012 Mar-Apr; 15(2):240-8. Epub 2011 Dec 15.
- The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.[Value Health. 2008]The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.Rocchi A, Menon D, Verma S, Miller E. Value Health. 2008 Jul-Aug; 11(4):771-83. Epub 2007 Dec 18.
- Review Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders.[Mental, Neurological, and Subs...]Review Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders.Levin C, Chisholm D. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4). 2016 Mar 14
- Comparison of two different models of anticoagulation management services with usual medical care.[Pharmacotherapy. 2010]Comparison of two different models of anticoagulation management services with usual medical care.Rudd KM, Dier JG. Pharmacotherapy. 2010 Apr; 30(4):330-8.
- Review Recommendations for Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation[ 2011]Review Recommendations for Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation. 2011 Nov
- Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patie...Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: Review of Canadian Economic Studies
- Guidance on 1.5 Tesla Magnetic Resonance Imaging Scanners Compared with 3.0 Tesl...Guidance on 1.5 Tesla Magnetic Resonance Imaging Scanners Compared with 3.0 Tesla Magnetic Resonance Imaging Scanners
- Third-Line Pharmacotherapy for Type 2 Diabetes — UpdateThird-Line Pharmacotherapy for Type 2 Diabetes — Update
- Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessme...Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment
Your browsing activity is empty.
Activity recording is turned off.
See more...